(Q24235478)

2

0 references

Stefania Cerri

object named as

Stefania Cerri

4

0 references

Pietro Battaglini

8

object named as

Luca Richeldi

0 references

author name string

Paolo Spagnolo

1

0 references

Fabrizio Luppi

3

0 references

Sara Balduzzi

5

0 references

E. Haydn Walters

Cochrane Database of Systematic Reviews

6

0 references

language of work or name

English

0 references

publication date

8 September 2010

0 references

published in

0 references

issue

9

0 references

page(s)

CD003134

0 references

cites work

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Anticoagulant therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

High dosages of D-penicillamine in pulmonary fibroses (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Cyclosporin as a treatment for interstitial lung disease of unknown aetiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Determinants of progression in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Interstitial lung disease resistant to corticosteroid therapy. Report of three cases treated with azathioprine or cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Acute exacerbations of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Strategies for treating idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Viruses and idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Fleischner Society: glossary of terms for thoracic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Emerging concepts in the pathogenesis of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Risk of cryptogenic fibrosing alveolitis in metal workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Epidemiology of interstitial lung diseases in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Familial idiopathic pulmonary fibrosis: clinical features and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

The clinical course of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Usual interstitial pneumonia: histologic correlation with high-resolution CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Incidence and prevalence of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Corticosteroids for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Early interstitial lung disease in familial pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Transbronchial biopsy and needle aspiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Clinical and pathologic features of familial interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Is idiopathic pulmonary fibrosis an environmental disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Histologic spectrum of idiopathic interstitial pneumonias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Immunomodulatory agents for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Colchicine Versus Prednisone as Treatment of Usual Interstitial Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

Efficacy of cyclosporin A for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Therapy of the idiopathic fibrosis of the lung

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Animal models of pulmonary fibrosis: how far from effective reality?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Different Therapies and Factors Influencing Response to Therapy in Idiopathic Diffuse Fibrosing Alveolitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

The epidemiology of interstitial lung diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Colchicine in the treatment of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134.PUB2

7 January 2021

10.1002/14651858.CD003134.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20824834

1 reference

Consolidated OpenCitations Corpus – April 2017